Research article

The impact of severity of hypertension on association of PGC-1α gene with blood pressure and risk of hypertension

Gaoqiang Xie¹, Dongshuang Guo², Ying Li*¹, Shengying Liang² and Yangfeng Wu*¹,3,4

Address: ¹Department of Epidemiology, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, The National Center for Cardiovascular Disease Control and Research, China, ²Department of Cardiovascular Epidemiology, Yu Xian Renmin Hospital, Shanxi, China, ³Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China and ⁴The George Institute, China, Beijing, China

Email: Gaoqiang Xie - gqxie72@163.com; Dongshuang Guo - guods2002@yahoo.com.cn; Ying Li* - yinglifw@263.net; Shengying Liang - lsy_1964@sina.com; Yangfeng Wu* - wuyf@bjmu.edu.cn

* Corresponding authors

Abstract

Background: Little is known about the impact of severity of hypertension on the association of genes with high blood pressure, which may cause the inconsistently reported associations of peroxisome proliferator-activated receptor-γ coactivator-1 α (PGC-1 α) gene with blood pressure.

Methods: A cardiovascular epidemiology survey and genotyping were performed in a population-based sample of 1642 apparently healthy residents (648 men and 994 women aged 35–91 years).

Results: After adjusting for age, sex, body mass index, and antihypertensive medication, G482S and +2962A/G polymorphisms were significantly associated with systolic blood pressures in hypertension patients with medication use (p = 0.023 and 0.022 for G482S and +2962A/G respectively) but not in all participants, normotensives, and patients with no medication use. Multivariable logistic models showed that the two polymorphisms were significantly associated with severe hypertension (SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg regardless of medication use), with an OR of 0.6 (95% confidence interval [CI]: 0.4–0.98) for S482S vs. G482G and an OR of 1.9 (95% CI: 1.2–3.0) for +2962G/G vs. +2962A/A, but not with regular hypertension (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg or current use of antihypertensive medications), with an OR of 0.9 (95% CI: 0.7–1.2) for S482S vs. G482G and an OR of 0.9 (95% CI: 0.7–1.4) for +2962G/G vs. +2962A/A. Haplotype combination analyses showed a significant synthetic effect (OR of severe hypertension for persons with G482X and +2962G/G = 2.6, 95% CI: 1.5–4.4, with reference to persons with S482S and +2962A/X).

Conclusion: In this study, we found that G482S and +2962A/G polymorphisms of PGC-1α gene were only significantly associated with severe hypertension defined by occasional clinic blood pressure measurements. This finding suggested severe hypertension rather than regular hypertension should be used as the outcome in studies on association of genes with blood pressure or hypertension, in order to have a better power.
Background
Hypertension is the most common risk factor for cardiovascular and cerebrovascular diseases and affects over 1 billion individuals worldwide[1,2]. Although some risk factors of hypertension such as high sodium intake, inactivity, obesity, familial history, etc. have been identified, genetic factors of hypertension at gene level remain unclear. This is possibly partly due to so called "minor effect" of the genes[3]. Also, it is possibly due to dilution effect from environment factors because of using a lower cut off of blood pressure to define hypertension cases. However, few studies have examined this hypothesis.

Peroxisome proliferator-activated receptors gamma coactivator 1 alpha (PGC-1α, Gene ID, No. 10891) is a coactivator of several nuclear receptors including peroxisome proliferator-activated receptors α and γ, thyroid hormone receptor, mineral corticoid receptor and estrogen receptors, and was considered involving in blood pressure regulation [4,5]. Recently, several western population studies have studied the associations of Gly482Ser (G482S) and +2962A/G single nucleotide polymorphisms (SNP) of PGC-1α gene with blood pressure [6-10]. However, the associations were inconsistent in different studies, even in the same ethnic populations. Moreover, the association has not been studied in Asian populations.

The aim of this study was to investigate whether the G482S and +2962A/G polymorphisms in the PGC-1α gene were associated with blood pressure and the impact of severity of hypertension on the association of PGC-1α Gene with blood pressure and risk of hypertension in a middle-aged and elderly population in China.

Methods

Study population
We drew our study participants from 10 villages in a northern Chinese population in 2004. To be recruited in the study, the participant must be a registered resident and living in the village in the year of survey. Among 8217 registered residents, 2835 met the inclusion criteria of living in the village in the year of survey and thus invited. Among the invited, 1998 accepted to participate and gave their informed consent; and 1701 had their genotypic information. We excluded 59 patients with myocardial infarction and stroke from analyzed population. We also excluded 5 participants with missing data of blood pressure. Finally 1642 participants were included in our analyses. The study was approved by the Ethical Committee of Fuwai Hospital according to the Declaration of Helsinki. The written informed consent was obtained from all participants.

Blood Pressure Measurement
Three BP measurements were obtained from each participant using a standard mercury sphygmomanometer by trained and certified observers, according to a standard protocol described in detail elsewhere[11,12]. The average of the 3 blood pressure readings were used to define hypertension and for analysis in the present paper. Current use of antihypertensive medication was determined by a "yes" or "no" answer to the Chinese equivalent of the question, "Have you taken antihypertensive drugs in the past 2 weeks?"

To explore the impact of severity of hypertension on the association between the gene and hypertension (or blood pressure), we used different cut offs to define hypertension. First, we defined hypertension using the current widely accepted criteria [2] as SBP ≥ 140mmHg or DBP ≥ 90 mmHg or current use of antihypertensive medications. We referred it as "regular hypertension" in this paper. Then, we also defined hypertension as SBP ≥ 160mmHg or DBP ≥ 100mmHg regardless of using antihypertensive medication. We referred it as "severe hypertension" in this paper.

Body Mass Index (BMI)
Body height was measured to the nearest centimeter (cm) using a standard right-angle device. Body weight was measured to the nearest kilogram by using a spring balance. Each participant was measured in typical indoor clothing, without shoes, and in a standing position. BMI was defined as weight/height² (kg/m²).

Genotyping
We genotyped the G482S (refSNP ID: rs8192678) and +2962A/G (refSNP ID: rs6821591) polymorphisms in the PGC-1α gene using DNA MassARRAY Technology[13,14]. Briefly, a fragment (approximately 100bp) containing the SNP site was amplified by PCR first. All PCR reactions were performed on an ABgene (#TF-0384), 384 well PCR plate. The sample plate and a 384 SpectroCHIP were placed on the deck of the SpectroPOINT robot. The robot transferred a few nanolitres of solution from the sample plate onto the chip and calibrant was transferred from reservoir onto calibrant patches of 384 SpectroCHIP. The chip was read in the Bruker Autoflex Mass Spectrometer system.

Statistical Analysis
SHEsis software[15] was used for Hardy-Weinberg equilibrium test, haplotype construction, and linkage analyses. Chi-square test ($\chi^2$) and odds ratio (OR) test were used for dichotomous variables. Logistic regression and ANOVA were used for adjustment for multiple covariates including sex, age, body mass index (BMI), and antihypertensive treatment, using Version 9.0 of SAS system for
Windows. A p-value less than 0.05 was considered statistically significant. Statistical power was calculated according to the following formula.

\[
Z_{1-\beta} = \frac{\sqrt{n}(p_1 - p_2) - Z_{1-\alpha/2}\sqrt{2p(1-p)}}{\sqrt{p_1(1-p_1) + p_2(1-p_2)}}
\]

In this formula, n is the total number of participants, p is total prevalence of hypertension, p1 and p2 are prevalence of hypertension in two compared genotypes groups, \(\alpha = 0.05\) was permitted as possibility of type I errors \((Z_{1-\alpha} = 1.96)\). Then \(Z_{1-\beta}\) is calculated and statistical power is estimated.

The difference of ORs was tested using Z-test according to the following formula.

\[
Z = \frac{\ln OR_1 - \ln OR_2}{\sqrt{\sigma^2_{\ln OR_1} + \sigma^2_{\ln OR_2}}}
\]

Results

General characteristics of participants
Table 1 showed general characteristics of the participants. Briefly, 648 men and 994 women participated in the study. The age varied from 35 to 91 years and was 53 years old on average. The prevalence was 48% for regular hypertension and 16% for severe hypertension. The severe hypertension accounted for 33.7% of the regular hypertension. 56.6% of regular hypertension and 59.3% of severe hypertension used antihypertensive medications in the past 2 weeks (Table 1).

Distribution of G482S and +2962A/G genotypes
The frequencies of wild-type (G482G), heterozygous (G482S), and variant genotypes (S482S) were 0.311, 0.496, and 0.192. The frequencies of wild-type (+2962A/A), heterozygous (+2962A/G), and variant genotypes (+2962G/G) were 0.512, 0.390, and 0.098 respectively. The distributions were consistent with Hardy-Weinberg equilibrium (HW-E) for G482S polymorphisms \((p = 0.780)\) but not for +2962A/G \((p = 0.018)\). In addition, the wild-type and variant allele frequencies for G482S poly-

Table 1: Characteristics of study population

| Variables                              | Values                        |
|----------------------------------------|-------------------------------|
| No. of participants                    | 1642                          |
| % of men (No.)                         | 39.46%(648)                   |
| Age, years                             | 52.8(10.2)                    |
| BMI, kg/m²                             | 24.2(3.7)                     |
| SBP, mmHg                              | 134.9(21.8)                   |
| DBP, mmHg                              | 82.9(10.9)                    |
| Regular hypertension*                  | 48.4%(795)                    |
| Severe hypertension**                  | 16.3%(268)                    |
| Antihypertensive medication use,%      | 27.41%(450)                   |
| Antihypertensive medication use among regular hypertension,% | 56.6%(450) |
| Antihypertensive medication use among severe hypertension,% | 59.3%(159) |
| Gly482Ser genotypes                    |                               |
| S482S                                  | 19.24%(316)                   |
| G482S                                  | 49.63%(815)                   |
| G482G                                  | 31.12%(511)                   |
| +2962A/G genotypes                     |                               |
| +2962A/A                               | 51.16%(840)                   |
| +2962A/G                               | 39.04%(641)                   |
| +2962G/G                               | 9.81%(161)                    |
| Haplotype combination                  |                               |
| S482S||+2962A/A                         | 19.0%(312)                    |
| S482S||+2962A/G                         | 0.2%(4)                       |
| S482S||+2962G/G                         | 0(0)                          |
| G482S||+2962A/A                         | 23.9%(392)                    |
| G482S||+2962A/G                         | 25.6%(421)                    |
| G482G||+2962A/A                         | 8.3%(136)                     |
| G482G||+2962A/G                         | 13.2%(216)                    |
| G482S||+2962G/G                         | 0.1%(2)                       |
| G482G||+2962G/G                         | 9.7%(159)                     |

Data are presented as mean(SD) or %/(n);

* Regular hypertension: SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg or current use of antihypertensive medications;

** Severe hypertension: SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg, regardless of medication use.
morphism were 0.559 and 0.441. Respective frequencies for the +2962A/G were 0.707 and 0.293. Estimated haplotype frequencies were 0.269, 0.291, 0.438, and 0.002 for the double-wild-type allele (482G/+2962A), the allele with the variant nucleotide at +2962(482G/+2962G), the allele with the variant nucleotide at G482S (482S/+2962A), double-variant allele (482S/+2962G), respectively. There were no significant differences between men and women in genotype, allele, or estimated haplotype frequencies.

**Linkage analyses of G482S and +2962A/G**

There was significant linkage disequilibrium between the +2962A/G and G482S polymorphism (D' = 0.981, p < 0.001). The distribution of the +2962A/G polymorphism was significantly associated with the distribution of the G482S polymorphism. The percentage of carriers of +2962 G/G were 0%, 0.3%, and 31.1% among carriers of S482S, G482S, and G482G genotypes, and the corresponding percents of carriers of the +2962A/A genotype were 98.7%, 48.1%, and 26.6% (p < 0.0001).

**Association of G482S and +2962A/G to blood pressure**

We compared blood pressure among genotype groups. After adjustment for age, sex, body mass index, and current use of antihypertensive medication, SBP and DBP were not significantly associated with G482S genotypes (p = 0.266) or +2962A/G genotypes (p = 0.103) (Table 2). Sex-specific analyses showed similar results (data not shown in table). In order to exclude the confounding effect of antihypertensive medication, we analyzed the associations in three subgroups: 1) normal blood pressure free from current use of antihypertensive medications; 2) hypertension free from current use of hypertensive medications; 3) current use of antihypertensive medications. We found a significant association of SBP to G482S genotypes (p = 0.023) and +2962A/G genotypes (p = 0.020) in subgroup 3 but not in subgroup 1 or 2 (Table 3).

**Association of G482S and +2962A/G to hypertension**

The prevalence of regular hypertension varied but did not differ among genotype groups for both G482S and +2962A/G. Adjustment for sex, age, body mass index did not change the results (Table 4).

The prevalence of severe hypertension differed at borderline significance among genotype groups for G482S and significantly for +2962A/G. After adjustment for age, sex, body mass index, and current use of antihypertensive medications, risk of severe hypertension was significantly lower for S482S in comparison with that for G482G (OR = 0.6; 95% confidence interval [CI]: 0.4–0.98) and significantly higher for +2962G/G than that for +2962A/A (OR = 1.9, 95% CI: 1.2–3.0). Sex-specific OR for +2962G/G vs. +2962A/A were 2.2(95%CI: 1.03–4.5) for men and 1.9(95%CI: 1.1–3.2) for women. However, sex-specific OR for G482S polymorphisms was no longer significant (OR = 0.6, 95% CI: 0.4–1.1 for men, OR = 0.7, 95% CI: 0.4–1.1 for women for S482S vs. G482G).

**Association of G482S and +2962A/G haplotype combination to hypertension**

According to results from Table 4, we grouped all possible combinations of haplotype into 4 groups as shown in Table 5. The results clearly showed a synthetic effect of G482S and +2962A/G in developing severe hypertension but not for regular hypertension.

**Post hoc analysis of power**

To understand whether our study has enough statistical power to conclude, we did analysis of power using the number of participants, prevalence of hypertension, and permitted possible type I error. The results showed that we had a power of 90% in analysis for the association of G482S genotype to the risk of severe hypertension, but it was only 46% for regular hypertension. For +2962A/G, we had 99% power for severe hypertension and only 4% for regular hypertension. For haplotype combination, we had

---

**Table 2: Mutivariable-adjusted means of blood pressure (mm Hg) and standard errors by Gly482Ser and +2962A/G polymorphisms in 1642 participants**

| Genotypes          | N    | SBP (mm Hg) | DBP (mm Hg) |
|--------------------|------|-------------|-------------|
| **G482S genotypes**|      |             |             |
| G482G              | 511  | 139.2 (0.9) | 85.2 (0.5)  |
| G482S              | 815  | 139.4 (0.7) | 84.7 (0.4)  |
| S482S              | 316  | 137.4 (1.1) | 84.6 (0.6)  |
| p values           |      | 0.266       | 0.630       |
| **+2962A/G genotypes**|   |             |             |
| +2962A/A           | 840  | 138.8 (0.7) | 84.7 (0.4)  |
| +2962A/G           | 641  | 138.6 (0.8) | 84.9 (0.4)  |
| +2962G/G           | 161  | 141.3 (1.5) | 85.4 (0.8)  |
| p values           |      | 0.103       | 0.695       |

Note: values were adjusted for age, sex, BMI, and current use of antihypertensive medications.
99% power for severe hypertension and only 14% for regular hypertension.

**Discussion**

Our study has a number of strengths. First, its study population was community-based. Secondly, International standardized methodology and quality control procedures were used, as part of the China Multicenter Collaborative Study of Cardiovascular Epidemiology[16]. Thirdly, genotyping was conducted in the Beijing Genomics Institute Life Tech Co. Ltd. which was one of genotyping centres for the International HapMap Consortium [17]. These gave us a better opportunity to detect the true association of our interested genotypes to hypertension.

In our study, G482S and +2962A/G polymorphisms and their haplotypes were found significantly associated with risk of severe hypertension but not with that of regular hypertension. These findings were confirmed by our findings that these two SNPs were significantly associated with blood pressure in patients using antihypertensive medications but not in all participants, normotensives or patients with no medication, and were independent of age, sex, body mass index, and antihypertension medication use. These findings are well in accordance with the current knowledge of hypertension that the disease is caused by not only genetic factors but also environment factors[3]. It is those who exposed to both genetic and environment factors develops severe hypertension and thus had a better power to detect the effect of gene, while those who exposed to only environment factors or genetic factors were not.

**Table 4: Prevalence and odds ratios (ORs) of regular and severe hypertension by PGC-1α polymorphisms in 1642 participants**

| Genotypes  | Total No. | Cases | Prevalence,% | OR₁(95%CI) | OR₂(95%CI) | p values for OR₁ vs. OR₂ |
|------------|-----------|-------|---------------|------------|------------|--------------------------|
| G482S genotypes | G482G | 511 | 261 | 51.1% | 1.0 | 91 | 17.8% | 1.0 |
| | G482S | 815 | 387 | 47.5% | 0.9(0.7–1.1) | 139 | 17.1% | 1.0(0.8–1.4) | 0.503 |
| | S482S | 316 | 147 | 46.5% | 0.9(0.7–1.2) | 38 | 12.0% | 0.6(0.4–0.98) | 0.177 |
| p values | 0.335 | 0.667 | 0.067 | 0.064 |
| +2962A/G genotypes | +2962A/A | 840 | 411 | 48.9% | 1.0 | 128 | 15.2% | 1.0 |
| | +2962A/G | 641 | 305 | 47.6% | 0.9(0.7–1.1) | 102 | 15.9% | 1.1(0.8–1.4) | 0.407 |
| | +2962G/G | 161 | 79 | 49.1% | 0.9(0.7–1.4) | 38 | 23.6% | 1.9(1.2–3.0) | 0.015 |
| p values | 0.863 | 0.623 | 0.030 | 0.011 |

* Regular hypertension: SBP ≥ 140 mm Hg or DBP ≥ 90mm Hg or current use of antihypertensive medications;
** Severe hypertension: SBP ≥ 160 mm Hg or DBP ≥ 100mm Hg, regardless of medication use.
OR₁: adjusted for sex, age, BMI.
OR₂: adjusted for sex, age, BMI, and antihypertensive medication.
P values for prevalence were from Chi-square test, p values for trend of ORs were from logistic regression, and p values for OR₁ vs. OR₂ were from Z-test.
develops light or moderate hypertension, which should be mostly composed of those caused by environment factors because of the much higher prevalence of environment factors, and it is hardly to detect the effect of gene among them. The dilution effect from environment factors plus the gene’s *minor effect* makes it impossible or very hardly to detect the effect of gene by using a lower cut off to define hypertension. Otherwise, a very large sample of more than tens or hundreds thousands participants is needed to make up, as shown by our post hoc analysis of power. As we knew, this is the first study found that PGC-1α gene variants had stronger associations with more severe hypertension. These findings have very important significance of generalization to other studies trying to identifying genes for hypertension development.

In addition, blood pressure lowering treatment in China is generally low (56.6% in this study), and it would be more likely that treated patients have a more severe hypertension and by that have a stronger link to genetic factors.

Our findings are also supported by the previous study done by Oberkofler and colleagues[6]. They used day time ambulatory blood pressure and defined hypertension as SBP > 140mm Hg or DBP > 90mm Hg or use of antihypertensive medication, and they found a significant association between G482S and hypertension in men[6]. Because the ambulatory blood pressure is lower than occasional clinic blood pressure, their findings were actually in accordance with ours.

Besides, we also found an additive synthetic effect of G482S and +2962A/G genotypes. Although the mechanisms to explain the effect remain unclear, some studies did provide useful evidence. There is substantial evidence for the existence of both monogenic and polygenic forms of essential hypertension, although these are believed to be modulated by both gene-environment and gene-gene interactions[8]. It is well known that both monogenic and polygenic forms of essential hypertension are often early-onset and more severe [3]. As a coactivator of PPARγ, PGC-1α regulates PPARγ gene expression which combined with its ligands (thiazolidinediones) to suppress angiotensin II (All) type 1 receptor (AT1R) gene expression both at the mRNA and protein levels in vascular smooth muscle cells[VSMCs][4]. Activation of AT1R by All binding triggers a variety of signal transduction pathways including the mitogen-activated protein (MAP) kinase pathway. All exerts many biological effects such as cell construction, proliferation, and migration of VSMCs that contributes to the progression of hypertension and atherosclerosis. PPARγ phosphorylation by the MAP kinase pathway may thus attenuate PPARγ-mediated AT1R gene transcription suppression through the inhibition of PPARγ activity[18]. PGC-1α is also a coactivator of other nuclear receptors, including thyroid hormone receptor, the mineralocorticoid and estrogen receptors (ER) α and β, which are also involved in blood pressure control[6-8,19].

Our study also has some limitations. First, there were 32% of none-responders in the study. The main reasons of not attending includes busy at farming work, out to do private small business, not having interest, and not like blood being drawn. The possible bias can not be totally eliminated though no reason was associated with hypertension or biological tests. Second, a significant deviation from the Hardy-Weinberg equilibrium (HW-E) was detected for the +2962A/G polymorphism in our study. This contrasts to the previous study by Oberkofler[6]. The findings that G482S genotypes in the same gene were in accordance with HW-E in both studies may not indicate that the deviation from HW-E was directly due to genotyping error. We resorted these polymorphisms independently using sequencing method in eight participants and ensured no genotyping error occurred. Finally, the possibility of type

### Table 5: Haplotype combination analyses of G482S and +2962A/G for regular and severe hypertension in 1642 participants

| Haplotype combinations | Regular hypertension* | | Severe hypertension** | | p values for OR1 vs. OR2 |
|------------------------|------------------------|---|------------------------|---|------------------------|
| S482X||+2962A/X | 316 | 147 | 46.5% | 1 | | 38 | 12.0% | 1.0 |
| S482X||+2962G/G | 0 | 0 | 0 | | | 0 | 0 | |
| G482X||+2962A/X | 1165 | 569 | 48.8% | 1.0(0.8–1.3) | 192 | 16.5% | 1.5(1.0–2.2) | 0.131 |
| G482X||+2962G/G | 161 | 79 | 49.1% | 1.0(0.7–1.3) | 38 | 23.6% | 2.6(1.5–4.4) | 0.006 |
| p values | 0.753 | 0.989 | 0.005 | 0.002 |

* Regular hypertension: SBP ≥ 140 mm Hg or DBP ≥ 90mm Hg or current use of antihypertensive medications;
** Severe hypertension: SBP ≥ 160 mm Hg or DBP ≥ 100mm Hg, regardless of medication use.

OR1: adjusted for sex, age, BMI. OR2: adjusted for sex, age, BMI, and antihypertensive medication.

X was used to represents all possible allele, e.g. +2962A/X stands for +2962A/A or +2962A/G.

P values for prevalence were from Chi-square test, p values for trend of ORs were from logistic regression, and p values for OR1 vs. OR2 were from Z-test.
1 error due to multiple tests is not eliminated but the systematic difference between regular and severe hypertension for both gene SNPs suggested that is not the case.

Conclusion
In this study, we found that G482S and +2962A/G SNPs of PGC-1α gene were only significantly associated with severe hypertension defined by occasional clinic blood pressure measurements. This finding suggested severe hypertension rather than regular hypertension should be used as the outcome in studies on association of genes and blood pressure or hypertension, in order to have a better power.

Competing interests
The author(s) declare that they have no competing interests.

Authors' contributions
GX did literature review, performed the statistical analysis and drafted the manuscript. DG and SL organized the study, applied for funding and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by grants 30471494 of the National Natural Science Foundation of China, grants 2001BA703B01 of the People’s Republic of China National 10th Five-Year Plan Science and Technology Key Projects. The authors thank Dr. Min Guo, Ye Tian, and Xianyi Kong for the DNA sampling and preparation for the genotyping. We thank all study participants in their cooperation and valuable contribution. We also thank Chiara Donfrancesco and other members from World Heart Federation CVD Epidemiology Fellows and Faculty list established by Steven Allender for their helps in Z-test of odds ratios.

References
1. Carretero OA, Oparil S. Essential hypertension. Circulation 2000, 101:17.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 7-complete version. Hypertension 2003, 42:1206.
3. Kwitek-Black AE, Jacob HJ. Gene-environment interaction. In Hypertension primer – The essentials of high blood pressure 2nd edition. Council on High Blood Pressure Research and American Heart Association; 1988:222-223.
4. Sugawara A, Takeuchi K, Urnou A, Ikeda Y, Arima S, Kudo M, Satoh K, Taniyama Y, Ito S. Transcriptional suppression of type 1 angiotensin II type 1 receptor genes expression by peroxisome proliferators-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 2001, 142:3125-3134.
5. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF. Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferators-activated receptor-γ. Circulation 2002, 105:2296-2302.
6. Oberkofler H, Holzl B, Esterbauer H, Xie M, Ighseder B, Kremler F, Paulweber B, Patsch W. Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Gene Locus: Associations with Hypertension in Middle-Aged Men. Hypertension 2003, 41:368-372.
7. Bk J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O: Mutation analysis of peroxisome proliferators-activated receptor-γ-coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 2001, 44:2220-2226.
8. Andersen G, Wegner L, Jensen DP, Glumer C, Tarnow L, Drivsholm T, Poulsen P, Hansen SK, Nielsen EM, Ek J, Mouritzen P, Vaag A, Parving HH, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O: PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites. Hypertension 2005, 45(4):565-570.
9. Cheurfa N, Reis AF, Dubois-Lafargue D, Bellanne-Chantelot C, Timsit J, Velho G. The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor-γ-coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J Mol Endocrinol 2005, 35:373-380.
10. People’s Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group: An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People’s Republic of China: Baseline Report from the P.R.C.-U.S.A. Collaborative Study. Circulation 1992, 85:1083-1096.
11. Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Koster H: Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 1999, 96:10016-10020.
12. Jurinke C, van den Boom D, Cantor CR, Koster H: Automated Genotyping using the DNA MassArray Technology. Methods Mol Biol 2002, 187:179-192.
13. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15:97-98.
14. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, Li Y, Rao X, Zhou B, Detrano R, Liu K: Estimation of 10-Year Risk of Fatal and Nonfatal Ischemic Cardiovascular Diseases in Chinese Adults. Circulation 2006, 114:2217-2225.
15. The International HapMap Consortium: A haplotype map of the human genome. Nature 2005, 437:1299-1320.
16. Chen S, Tan W, Huang J, Yang W, Gu D. Peroxisome Proliferator-Activated Receptor-g Coactivator-1α Polymorphism Is Not Associated with Essential Hypertension and Type 2 Diabetes Mellitus in Chinese Population. Hypertens Res 2004, 27:813-820.
17. Knuts D, Kaal A, Krali A: A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 2000, 20:2411-2422.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2261/7/33/prepub